Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

Share Price is delayed by 15 minutes
Get Live Data
160.00    0.00 (0.00%)
Bid:
120.00
Ask:
200.00
Spread: 80.00 (66.667%)
Market Cap: £77.39m
SPSC Live PriceLast checked at - London Stock Exchange

Intraday Spectra (di/ S) Share Chart

Appointment of Chief Financial Officer

23 Jan 2017 07:00

RNS Number : 7780U
Spectra Systems Corporation
23 January 2017
 

Spectra Systems Corporation

("The Company" or "Spectra Systems")

Appointment of Chief Financial Officer

Spectra Systems, a leading supplier of authentication technology for banknotes, brand authentication and tax stamps, is delighted to announce that, subject to the satisfactory conclusion of due diligence, it has agreed to appoint Brian E McLain C.P.A. (aged 41) as its new Chief Financial Officer.

Brian McLain started his career in 1997 at Arthur Andersen prior to working as a senior accountant at Excelergy Corporation, a software business, located in Lexington, MA from 2000 until 2003. Until late 2006, he then progressed through various roles at International Power, a UK owned power producer located in Marlborough MA, prior to joining SeraCare Life Sciences, Inc, a manufacturer of biological products for the diagnostics and drug discovery markets located in Milford MA. At SeraCare, which was quoted on NASDAQ prior to being bought out in 2012, he progressed from the role of Corporate Controller to Vice President, Finance & Business Solutions. In 2014, he then joined OMNIlife Science Inc., a manufacturer and distributor of orthopaedic devices located in Raynham, MA, in the role of Corporate Controller.

A further announcement will be made upon the conclusion of due diligence by certain of Spectra's customers and the completion of standard regulatory AIM background checks. This due diligence is expected to be completed by no later than February 2017. In the meantime, Doug Anderson, the previous Chief Financial Officer is continuing to assist Spectra as necessary.

Brian McLain joined SeraCare Life Sciences Inc. ("SeraCare") in January 2007, at which point it was already in a bankruptcy process. All creditors were subsequently settled and SeraCare exited the bankruptcy process. There are no other matters which are required to be announced pursuant to paragraph (g) of Schedule 2 to the AIM Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

Dr. Nabil Lawandy, CEO of Spectra Systems, stated: "I am delighted to welcome Brian to Spectra Systems and believe that his extensive financial experience in both private and public businesses as well as his experience in technology driven companies will be of immense value to us."

Enquiries:

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer Tel: +1 (0) 401 274 4700

WH Ireland Limited

Chris Fielding (Head of Corporate Finance) Tel: +44 (0) 20 7220 1650

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEFFWSFWSEFF
Date   Source Headline
22nd May 20262:45 pmRNSAdditional Sensor order
16th Apr 20267:00 amRNSExercise of Options and Total Voting Rights
8th Apr 20267:00 amRNSExercise of Options and Total Voting Rights
30th Mar 20267:00 amRNSAudited results for year ended 31 December 2025
5th Feb 20267:00 amRNSExecuted Contract with HMRC for Vaping Duty Stamps
16th Jan 20267:00 amRNSSuccessful Bid for HMRC Vaping Duty Stamps Scheme
8th Dec 20257:00 amRNSTransaction in Own Shares & TVR
26th Nov 20257:01 amRNSTransaction in Own Shares & TVR
26th Nov 20257:00 amRNSMaintenance contract for new sensors
25th Nov 20257:00 amRNSShare Buyback Programme
16th Oct 20257:00 amRNSAppointment of Finance Director
29th Sep 20257:00 amRNSInterim Results for Six Months Ended 30 June 2025
9th Sep 20252:59 pmRNSNotice of Interim Results
27th Jun 20257:00 amRNSExercise of Options
24th Jun 20254:48 pmRNSAnnual General Meeting Lack of Quorum
11th Jun 20257:00 amRNSNotice of AGM
27th May 20255:33 pmRNSAppointment of Finance Director
9th Apr 20254:55 pmRNSHolding(s) in Company
7th Apr 20257:00 amRNSExercise of Options & Removal of Reg S
31st Mar 20257:00 amRNSAudited results for year ended 31 December 2024
9th Jan 20257:00 amRNSExercise of Options
18th Dec 20243:58 pmRNSExercise of Options
18th Dec 20247:00 amRNS$9.4M downpayment on sensor manufacturing contract
21st Oct 20244:00 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
20th Aug 20244:35 pmRNSRemoval of Reg S restrictions from common stock
30th Jul 20247:00 amRNSAnnual General Meeting Lack of Quorum
18th Jul 20244:52 pmRNSHolding(s) in Company
16th Jul 20247:00 amRNSNew $37.9 million sensor manufacturing contract
15th Jul 20247:00 amRNSChange of Nominated Adviser and Broker
28th Jun 20241:46 pmRNSReplacement: Posting of Annual Report
28th Jun 202410:14 amRNSPosting of Annual Report and Notice of AGM
3rd Jun 20247:00 amRNSIssue of Equity & Update to Dividend Timetable
27th Mar 20247:00 amRNSAudited results for 12 months ended 31 Dec 2023
11th Jan 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
28th Dec 20237:00 amRNSExercise of Options
21st Dec 202312:15 pmRNSCompletion of Acquisition
15th Dec 20234:35 pmRNSExercise of Options and transfer of shares
4th Dec 20237:00 amRNSAcquisition of Cartor Holdings Limited
6th Nov 20234:43 pmRNSTR-1
12th Oct 20237:00 amRNSLargest Central Bank Consumables Order
25th Sep 20237:00 amRNSInterim Results for Six Months Ended 30 June 2023
7th Jul 20236:01 pmRNSRemoval of Regulation S restrictions from shares
26th Jun 20233:22 pmRNSAnnual General Meeting Lack of Quorum
30th May 20237:00 amRNSAppointment of Chief Financial Officer
25th Apr 20237:00 amRNSAdditional Sensor Services Contract Amendment
24th Apr 20237:00 amRNSResignation of Chief Financial Officer
19th Apr 20237:05 amRNSRemoval of Reg S restrictions from common stock
6th Apr 20237:00 amRNSExercise of Options
31st Mar 20235:14 pmRNSRemoval of Reg S restrictions from shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.